Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Contributing factors to variability in biological indicator performance data.

J E Moldenhauer1

  • 1Jordan Pharmaceuticals, Inc., Elk Grove Village, Illinois, USA.

PDA Journal of Pharmaceutical Science and Technology
|February 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parametric release--much ado about nothing.

PDA journal of pharmaceutical science and technology·2000
Same author

Determining the capability of a drug product to be terminally sterilized: a case study involving a heat-sensitive, oxygen-sensitive drug product.

Pharmaceutical development and technology·1998
Same author

Determining whether a product is steam sterilizable.

PDA journal of pharmaceutical science and technology·1998
Same author

Microbial barrier assessment of Tyvek stopper packaging for rubber closures.

PDA journal of pharmaceutical science and technology·1996
Same author

Antimicrobial resistance of three species of Bacillus to thirty various antimicrobial agents.

PDA journal of pharmaceutical science and technology·1996
Same author

Heat resistance of Bacillus coagulans spores suspended in various parenteral solutions.

PDA journal of pharmaceutical science and technology·1995
Same journal

A PAT-aligned framework for installing and operating particle counting systems to detect pre-limit particle-size distribution shifts in ISO-8 (non-sterile) controlled areas.

PDA journal of pharmaceutical science and technology·2026
Same journal

Using Positive Controls to Define the Defect Detection Range for CCIT Method Development and Validation.

PDA journal of pharmaceutical science and technology·2026
Same journal

Patient-Centric Drug Delivery: Establishing Injection Hold Time Limits for Large Volume Autoinjectors.

PDA journal of pharmaceutical science and technology·2026
Same journal

Gas flow through micro-capillaries â which flow law is most suitable to predict the flow rate through micro-capillaries?

PDA journal of pharmaceutical science and technology·2026
Same journal

Peer Review.

PDA journal of pharmaceutical science and technology·2026
Same journal

In-situ Verification of Disinfection Rotation for Contamination Control.

PDA journal of pharmaceutical science and technology·2026
See all related articles

Pharmaceutical manufacturers must verify biological indicator accuracy due to new regulations. Many found discrepancies between labeled and verified values, requiring resolution and prevention strategies for future studies.

Area of Science:

  • Microbiology
  • Pharmaceutical Science
  • Regulatory Affairs

Background:

  • Regulatory and compendial bodies now mandate verification of biological indicator (BI) data.
  • Pharmaceutical manufacturers faced new requirements for validating thermal death time (D-value) and organism counts.
  • Implementation of these verification procedures revealed discrepancies in BI data.

Purpose of the Study:

  • To address discrepancies found in biological indicator verification.
  • To provide strategies for resolving current data inconsistencies.
  • To outline methods for preventing future discrepancies in BI verification studies.

Main Methods:

  • Review of regulatory and compendial requirements for biological indicators.
  • Analysis of common discrepancies between labeled and verified BI data.

Related Experiment Videos

  • Development of conceptual frameworks for discrepancy resolution and prevention.

    • Main Results:

    • Significant discrepancies exist between labeled and verified biological indicator values.
    • Current verification practices highlight a need for standardized protocols.
    • The study identifies key areas for improvement in BI data management.

    Conclusions:

    • Pharmaceutical manufacturers must proactively address BI data verification.
    • Implementing robust verification protocols is crucial for regulatory compliance.
    • The findings offer a pathway to enhance the reliability of biological indicators in pharmaceutical manufacturing.